PT -期刊文章盟梅勒妮Metral盟——伊莎贝拉盟右路放倒,海伦Kovari AU -亚历山德拉Calmy盟Klemens Gutbrod Andreas Monsch AU -彼得brgger盟盟-凯瑟琳亲爱的盟Renaud Du Pasquier盟马提亚Cavassini TI -三个筛选问题的敏感性和特异性认知障碍(P2.303) DP - 2017年4月18日TA -神经病学PG - P2.303 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P2.303.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P2.303首页.full所以Neurology2017 4月18日;88 AB -目的:本研究旨在确定筛选问题的敏感性和特异性检测艾滋病毒相关神经认知障碍(手)。背景:为了提高检测的手,欧洲艾滋病临床社会(eac)建议问三个eac筛选问题(收)有关记忆丧失、精神放缓,和注意力障碍。设计/方法:在这个未来的正在进行的多中心队列研究嵌入到瑞士艾滋病队列研究,899例45岁以上的人登记,问先生之前进行一次彻底的标准化的神经心理学评估包括情绪量表(鉴定)。敏感性,特异性,阳性(PPV)和负(NPV)预测值先生的神经认知障碍(非传染性疾病)计算。结果:我们的队列(平均年龄55±7.5年,80%的男性,92%的白人)有高比例的检测不到病毒载量(96%,VL< 50拷贝/毫升;当前的CD4细胞632 / mm3和中值值最低点CD4细胞180 / mm3)。收,25%回答“是的绝对”至少一次。在这组,非传染性疾病的患病率是51%:25%,主要是由于手和26%的混杂因素。其中674名患者筛选-先生,非传染性疾病的患病率是37%:27.5%,主要是由于手和9.5%的“其他”。 Sensitivity and specificity of the ESQ were respectively 31.6% and 79.4%. The corresponding PPV and NPV were 0.51 and 0.62, respectively 0.34 and 0.69 when the analysis was restricted to HAND. When asymptomatic neurocognitive impairment (ANI) was excluded from NCD definition and considered as normal, PPV and NPV were respectively 0.30 and 0.90. The association between positive answers both at ESQ and CES-D was statistically significant (p <0.001).Conclusions: The ESQ exhibited a poor PPV and NPV for the diagnosis of HAND. When ANI was excluded, the ESQ had a good NPV to rule out symptomatic NCD. Higher depression scores were significantly associated with positive answers to the ESQ.Disclosure: Dr. Métral has nothing to disclose. Dr. Locatelli has nothing to disclose. Dr. Kovari has nothing to disclose. Dr. Calmy has nothing to disclose. Dr. Gutbrod has nothing to disclose. Dr. Brugger has nothing to disclose. Dr. Monsch has received personal compensation for activities with Novartis and Schwabe. Dr. Monsch has received research support from Zinfandel Pharmaceuticals. Dr. Darling has nothing to disclose. Dr. Du Pasquier has received personal compensation for activities with Biogen, Novartis, Abbott, ViiV, EMD Serono, and Merck Sharp & Dohme Ltd. Dr. Cavassini has received research support from Merck Sharp & Dohme Ltd., and Gilead.